Hansoh Pharmaceutical Group Company Limited Share Price and Company Fundamentals
Last traded: Today at 8:08 AM
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Key Metrics
PE ratio
38.47
PB ratio
5.85
Dividend yield
1.34%
Beta
0.64
Market cap
$205.85B
Enterprise value
$178.84B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 9313 |
| Website | https://www.hspharm.com |
| Mailing address | 287 Xiangke Road Pudong New District Shanghai 201210 China |
| Phone / Fax | 86 40 0828 5227 / |
Dividends
Dividend yield
1.34%
Dividend amount
$0.46
Payout ratio
38.12%
5Y Avg. yield
-%
Hansoh Pharmaceutical Group Company Limited paid $0.46 dividend and the ex-dividend date was 22 Sep 2025.The dividend payout ratio is 38.12%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.3692 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Hansoh Pharmaceutical Group Company Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Huijuan Zhong | Founder, Chairlady & CEO | 63 | |
| Dr. Aifeng Lyu | Executive Director | 47 | |
| Ms. Yuan Sun | Executive Director | 38 | |
| Mr. Min Hu | Chief Financial Officer | 48 | |
| Dr. Shan Jiang | Chief Technology Officer | 55 | |
| Dr. Chih-Hung Lee | Chief Science Officer | 65 | |
| Mr. Chuanhe Xu | Senior Vice President | 61 | |
| Dr. Weiyong Sun | Chief Business Officer | 54 | |
| Dr. Xiaoqing Zhang | Chief Medical Officer | 51 | |
| Ms. Shengli Zhong | Joint Company Secretary & Senior VP | 57 |
Profitability and management effectiveness
Profit margin
36.25%
Operating margin
42.42%
Return on assets
8.35%
Return on equity
16.21%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Hansoh Pharmaceutical Group Company Limited is 205.85B and its enterprise value is 178.84B. The enterprise value to revenue ratio of 3692 is 13.56. The enterprise value to EBITDA ratio of 3692 is 37.16.
The 3692's stocks Beta value is 0.64 making it 36% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Hansoh Pharmaceutical Group Company Limited (HKEX:3692) Frequently Asked Questions
1. What is Hansoh Pharmaceutical Group Company Limited's Stock Symbol?
Hansoh Pharmaceutical Group Company Limited trades on HKEX under the ticker symbol "3692".
2. What is Hansoh Pharmaceutical Group Company Limited's stock price today?
One share of 3692 stock can currently be purchased for approximately $34.62.
3. How can I contact Hansoh Pharmaceutical Group Company Limited?
Hansoh Pharmaceutical Group Company Limited's mailing address is 287 Xiangke Road Pudong New District Shanghai 201210 China. The company can be reached via phone at 86 40 0828 5227.
4. What is Hansoh Pharmaceutical Group Company Limited's official website?
The official website of Hansoh Pharmaceutical Group Company Limited is https://www.hspharm.com.